A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR

作者：D Dupoiron; A Stachowiak; O Loewenstein; A Ellery; W Kremers; B Bosse; M Hopp

来源：European Journal of Pain, 2017, 21(9): 1528-1537.

DOI：10.1002/ejp.1054

Abstract(#br)Background(#br)Oxycodone/naloxone ( OXN PR ) is a prolonged‐release formulation containing oxycodone and naloxone in a 2:1 ratio. This study aimed to evaluate the tolerability and efficacy of doses up to OXN 160/80 mg PR compared with oxycodone prolonged‐release formulation (Oxy PR ) in...